Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Melanoma 137Carcinoma, Non-Small-Cell Lung 38Carcinoma, Renal Cell 33Neoplasm Metastasis 32Prostatic Neoplasms 22Brain Neoplasms 21Lung Neoplasms 20Pancreatic Neoplasms 19Uveal Melanoma 17Neoplasms 17Carcinoma, Hepatocellular 13Breast Neoplasms 13Sarcoma 12Skin Neoplasms 10Kidney Neoplasms 10Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Glioblastoma 9Triple Negative Breast Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Transitional Cell 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Recurrence 6Myelodysplastic Syndromes 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5

Interventions

Mitotane 7Cisplatin 6pembrolizumab 5Etoposide 3Doxorubicin 3camrelizumab 2apatinib 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Cytoreduction Surgical Procedures 2sodium thiosulfate 1iodophenyl metomidate 1fludarabine phosphate 1dostarlimab 1cemiplimab 1cabozantinib 1cabazitaxel 1antineoplaston AS 2-1 1antineoplaston A10 1Suramin 1Sunitinib 1Streptozocin 1Sorafenib 1Radiation 1Paclitaxel 1Observation 1Nivolumab 1Megestrol Acetate 1Lymph Node Excision 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Adrenocortical Carcinoma × Ipilimumab × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡